Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial
Journal of Clinical Oncology · 10.02.2024 · 42 (5) · 571-583
DOI: 10.1200/jco.23.00339 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2024. Verfasst von Joaquin Mateo und 22 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Campus, Barcelona, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Campus, Barcelona, Spain.
- The Institute of Cancer Research and Royal Marsden, London, United Kingdom.
- Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
- Centre de recherche du Centre Hospitalier de l'Université de Montréal/CRCHUM, Université de Montréal, Montreal, QC, Canada.
- Carolina Urologic Research Center, Myrtle Beach, SC.
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
ORCID-Profile: Joaquin Mateo, Johann S de Bono, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Neeraj Agarwal, David Olmos, Mustafa Özgüroğlu, Niven Mehra, Jae Young Joung, Ernesto Korbenfeld, Natalia Lukashchuk, Maha Hussain
Förderung
- Medical Research Council
Zitieren
APA
Mateo, J., de Bono, J. S., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Agarwal, N., Olmos, D., Thiery-Vuillemin, A., Özgüroğlu, M., Mehra, N., Matsubara, N., Young Joung, J., Padua, C., Korbenfeld, E., Kang, J., Marshall, H., Lai, Z., …, & Hussain, M. (2024). Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. Journal of Clinical Oncology, 42(5), 571-583. https://doi.org/10.1200/jco.23.00339
Vancouver
Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. Journal of Clinical Oncology. 2024;42(5):571-583. doi:10.1200/jco.23.00339
BibTeX
@article{Mateo2024,
author = {Mateo, Joaquin and de Bono, Johann S and Fizazi, Karim and Saad, Fred and Shore, Neal and Sandhu, Shahneen and Chi, Kim N and Agarwal, Neeraj and Olmos, David and Thiery-Vuillemin, Antoine and Özgüroğlu, Mustafa and Mehra, Niven and Matsubara, Nobuaki and Young Joung, Jae and Padua, Charles and Korbenfeld, Ernesto and Kang, Jinyu and Marshall, Helen and Lai, Zhongwu and Barnicle, Alan and Poehlein, Christian and Lukashchuk, Natalia and Hussain, Maha},
title = {Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {5},
pages = {571--583},
doi = {10.1200/jco.23.00339}
}
EUVIMED